Evaluation of the Efficacy and Safety of DM934 Versus Théalose on Eye Dryness
Multicentric, Randomized, Comparative Clinical Study on the Evaluation of the Efficacy and Safety of DM934 Versus Théalose on the Treatment of Moderate to Severe Ocular Dryness
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Laure Chauchat
- Phone Number: +33 (0)4 89 08 90 98
- Email: laure.chauchat@horus-pharma.com
Study Locations
-
-
-
Aix-en-Provence, France
- Eurofins DERMSCAN
-
Bordeaux, France
- Eurofins EVIC
-
-
-
-
-
Gdańsk, Poland
- Eurofins Dermscan Poland
-
-
-
-
-
Valladolid, Spain
- IOBA
-
-
-
-
-
London, United Kingdom
- Ocular Technology Group
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject with a moderate to severe dry eye syndrome needing artificial tears in the 3 months preceding the inclusion.
- Subject having used only artificial tears without preservative (NaCl 0.9%, Larmabak®) during 1 to 2 weeks before inclusion (up to 6 times a day) (given during wash-out period).
- Subject with a score ≥ 18 for the OSDI (Ocular Surface Disease Index).
Subject with at least one eye with:
- Global ocular staining (cornea and conjunctiva) ≥4 and ≤9 on the Oxford scale (0 to 15)
AND one of the following criteria:
- Schirmer test ≥ 3 mm/5 min and ≤ 9 mm/5 min OR
Sum of 3 measurements of Tear film Break-Up Time (TBUT) ≤ 30s.
- Subject, having given freely and expressly his/her informed consent.
- Subject who is able to comply with the study requirements, as defined in the present CIP, at the Investigator's appreciation.
- For applicable countries: subject being affiliated to a health social security system.
- Female subjects of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.
Exclusion Criteria:
- Far best corrected visual acuity < 1/10 (according to Snellen Chart)
Subject with severe ocular dryness with one of these conditions:
- Eyelid or blinking malfunction
- Corneal disorders not related to dry eye syndrome
- Ocular metaplasia
- Filamentous keratitis
- Corneal neovascularization
- Subject with severe meibomian gland dysfunction (MGD).
- History of ocular trauma, infection or inflammation, not related to dry eye syndrome within the last 3 months prior to the inclusion.
- History of ocular allergy or ocular herpes within the last 12 months.
- Any troubles of the ocular surface not related to dry eye syndrome .
- Subjects who underwent ocular surgery, including laser surgery, in either eye within the last 6 months.
- Use of the following ocular treatments: isotretinoïd, cyclosporine, tacrolimus, sirolimus, pimecrolimus, punctual plugs during the month preceding the inclusion.
- Subjects who have received ocular therapy (either eye) with any ophthalmic medication, except tear substitutes, within 2 weeks prior to study start or expected to receive ocular therapy during the study.
- Any not stabilised systemic treatment, which can have an effect on performance or safety criteria, at the investigator appreciation.
- Pregnant or nursing woman or planning a pregnancy during the study.
- Subject deprived of freedom by administrative or legal decision.
- Subject in a social or health institution.
- Subject who is under guardianship or who is not able to express his/her consent.
- Subject being in an exclusion period for a previous study.
- Subject suspected to be non-compliant according to the Investigator's judgment.
- Subject wearing contact lenses during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Investigational product
|
1 drop in each eye, 4 to 6 times per day
|
|
Active Comparator: Comparator
|
1 drop in each eye, 4 to 6 times per day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cornea and conjunctiva staining (Oxford score)
Time Frame: 35 days
|
Evaluation of the non-inferiority of DM934 in comparison with Théalose, in terms of cornea and conjunctiva staining (Oxford score), on worse eye
|
35 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tear-Film Break Up Time (TBUT) (performance)
Time Frame: 84 days
|
Main change from baseline of Tear-Film Break Up Time (TBUT) in the worse eye and contralateral eye
|
84 days
|
|
Cornea and conjunctiva staining (Oxford score) (performance)
Time Frame: 84 days
|
Main change from baseline of cornea and conjunctiva staining (Oxford score) in the worse eye and contralateral eye
|
84 days
|
|
Global performance by the investigator (performance)
Time Frame: 84 days
|
Global performance assessment by the investigator using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)
|
84 days
|
|
Cornea and conjunctiva staining (Oxford score) (performance)
Time Frame: 35 days
|
Main change from baseline of cornea and conjunctiva staining (Oxford score) in the worse eye and contralateral eye
|
35 days
|
|
Tear-Film Break Up Time (TBUT) (performance)
Time Frame: 35 days
|
Main change from baseline of Tear-Film Break Up Time (TBUT) in the worse eye and contralateral eye
|
35 days
|
|
OSDI (questionnaire)(performance)
Time Frame: 35 days
|
Main change from baseline of Ocular Surface Disease Index (OSDI) score
|
35 days
|
|
OSDI (questionnaire)(performance)
Time Frame: 84 days
|
Main change from baseline of Ocular Surface Disease Index (OSDI) score
|
84 days
|
|
Van Bijsterveld score (performance)
Time Frame: 35 days
|
Main change from baseline of Van Bijsterveld score (lissamine green staining) in the worse eye and contralateral eye
|
35 days
|
|
Van Bijsterveld score (performance)
Time Frame: 84 days
|
Main change from baseline of Van Bijsterveld score (lissamine green staining) in the worse eye and contralateral eye
|
84 days
|
|
Schirmer test (performance)
Time Frame: 35 days
|
Main change from baseline of Schirmer test result in the worse eye and contralateral eye
|
35 days
|
|
Schirmer test (performance)
Time Frame: 84 days
|
Main change from baseline of Schirmer test result in the worse eye and contralateral eye
|
84 days
|
|
Dry eye symptoms (performance)
Time Frame: 35 days
|
Mean change from Baseline in the global sum score of dry eye symptoms at D84 : discomfort,burning, stinging,eye dryness sensation, itching,foreign body sensation,photophobia, blurred vision.Each graded from 0 to 10
|
35 days
|
|
Dry eye symptoms (performance)
Time Frame: 84 days
|
Mean change from Baseline in the global sum score of dry eye symptoms at D84 : discomfort,burning, stinging,eye dryness sensation, itching,foreign body sensation,photophobia, blurred vision.Each graded from 0 to 10
|
84 days
|
|
Global performance by the investigator (performance)
Time Frame: 35 days
|
Global performance assessment by the investigator using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)
|
35 days
|
|
Global performance by the patient (performance)
Time Frame: 35 days
|
Global performance assessment by the patient using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)
|
35 days
|
|
Global performance by the patient (performance)
Time Frame: 84 days
|
lobal performance assessment by the patient using a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)
|
84 days
|
|
Number of Adverse Events (safety)
Time Frame: 84 days
|
Collection of ocular and systemic adverse events
|
84 days
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lacrimal meniscus height (exploratory, optional)
Time Frame: 35 days
|
Main change from baseline of lacrimal meniscus height in the worse eye and contralateral eye
|
35 days
|
|
Lacrimal meniscus height (exploratory, optional)
Time Frame: 84 days
|
Main change from baseline of lacrimal meniscus height in the worse eye and contralateral eye
|
84 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ewa Paw, MD, Eurofins Dermscan Poland
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 23E0548
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.